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Abstract 
The inner membrane vesicle system is a complex transport system that includes endocytosis, 
exocytosis and autophagy. However, the details of the intracellular trafficking pathway of 
nanoparticles in cells have been poorly investigated. Here, we investigate in detail the intracellular 
trafficking pathway of protein nanocapsules using more than 30 Rab proteins as markers of 
multiple trafficking vesicles in endocytosis, exocytosis and autophagy. We observed that 
FITC-labeled protein nanoparticles were internalized by the cells mainly through Arf6-dependent 
endocytosis and Rab34-mediated micropinocytosis. In addition to this classic pathway: early 
endosome (EEs)/late endosome (LEs) to lysosome, we identified two novel transport pathways: 
micropinocytosis (Rab34 positive)-LEs (Rab7 positive)-lysosome pathway and EEs-liposome 
(Rab18 positive)-lysosome pathway. Moreover, the cells use slow endocytosis recycling pathway 
(Rab11 and Rab35 positive vesicles) and GLUT4 exocytosis vesicles (Rab8 and Rab10 positive) 
transport the protein nanocapsules out of the cells. In addition, protein nanoparticles are observed 
in autophagosomes, which receive protein nanocapsules through multiple endocytosis vesicles. 
Using autophagy inhibitor to block these transport pathways could prevent the degradation of 
nanoparticles through lysosomes. Using Rab proteins as vesicle markers to investigation the detail 
intracellular trafficking of the protein nanocapsules, will provide new targets to interfere the 
cellular behaver of the nanoparticles, and improve the therapeutic effect of nanomedicine. 
Key words: Nanomedicine; Endocytosis; Autophagy; Exocytosis; Protein nanocapsules. 
Introduction 
Most human diseases, including cancer, diabetes 
and neurodegenerative diseases, are caused by 
mutations in a class of specific genes. Mutations in 
these genes can induce the transcription of 
dysfunctional or nonfunctional proteins that cause 
pathogenesis. Protein therapy is one of the safest and 
most direct approaches for the treatment of disease by 
replenishing functional proteins within unhealthy 
cells [1]. However, the poor stability and low cellular 
permeability of the proteins makes protein therapy 
difficult to apply clinically [2]. In recent years, a novel 
delivery platform based on nanocapsules was 
developed to deliver proteins to target cells. 
Nanocapsules are designed to consist of a protein core 
and a thin permeable degradable polymeric shell 
[3-5]. Once the degradable nanocapsules enter the 
cells, their shells break down and release the core 
proteins into the cytoplasm [5].  
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Including the newly designed protein 
nanocapsules, many biodegradable nanocarried 
particles have been developed, such as 
PLGA(poly(lactic-co-glycolic acid)-based 
nanoparticles, micelles, chitosan and microgels [6-10]. 
Most of these nanocarriers are used as drug 
nano-vehicles and have promising effects for drug 
delivery, such as a long lifecycle in the blood stream, 
targeting to specific cells with ligands on the surface 
of the particles or cells and multiple drug targets [7, 
11]. These designed nanocarriers must enter the cells 
and release the drugs to the target cells to execute 
their missions. Most nanoparticles enter the target 
cells through endocytosis [12]. The main endocytosis 
pathways are either clathrin dependent or clathrin 
independent [12]. The clathrin independent pathways 
include the micropinocytosis, caveolin dependent and 
caveolin independent (Arf-6, Flotillin, Cdc42 and 
RhoA- dependent) pathways [12]. After crossing the 
cell membrane, the nanoparticles are sequestered in 
vesicles. These vesicles are transported to early 
endosomes (EEs) and late endosomes (LEs) and 
finally fuse with lysosomes [12, 13]. Most developed 
nanoparticles, including PLGA-based nanoparticles, 
micelles, chitosan and microgels, have been shown to 
traffic in this classic endocytosis pathway. 
Modification of nanoparticles with various ligands, 
such as histidine, detergent and cell membrane 
penetrating peptides, enhances the nanoparticles’ 
escape from the endo-lysosome system [14-16].  
The inner membrane vesicle system is a complex 
transport system that includes endocytosis, exocytosis 
and autophagy, which is responsible for the transport 
of various macromolecules between different 
organelles in the cells [17-19]. The crosstalk between 
endocytosis, exocytosis and autophagy makes these 
networks much more complex. Other endocytotic 
pathways exist in addition to the EEs-LEs-lysosome 
pathway. Recycling of the endosome system is 
responsible for delivering protein receptors back to 
the cell membrane [12]. The exocytosis pathway is 
responsible for the transportation of mature proteins 
from the Golgi body to the cell membrane or for 
secreting the proteins out of the cells [19]. Autophagy 
is a cellular process that engulfs cellular components, 
such as cytoplasm, damaged mitochondrial, 
aggregated proteins and invading pathogens [18]. 
Moreover, there are multiple pathways that exist in 
endocytosis, recycling endocytosis, exocytosis and 
autophagy. However, most studies focus on the 
intracellular trafficking and, accordingly, the design 
of nanocarriers is limited to the EEs-LEs-lysosome 
pathway. The trafficking pathways such as recycling 
endosomes, exocytosis and autophagy of the 
nanoparticles in the cells are poorly investigated and 
unknown.  
The Rab protein family consists of 
GTPases/GTP- binding proteins that are evolutionary 
conserved from yeast to humans. Rab proteins have 
various cellular functions, including protein 
trafficking, transmembrane signal transduction and 
the fusion of vesicles between different organelles 
[20]. More than 70 human Rab proteins have been 
identified, and the functions of 30 Rab proteins have 
been identified [21]. Most of these Rab proteins are 
involved in the trafficking of vesicles in and across 
endocytosis, recycling endocytosis and exocytosis 
pathways [22]. Rab5 and Rab7 have been well studied 
and have become the most important organelle 
identity markers of EEs and LEs in the endocytic 
pathway, respectively [22]. To investigate in detail, 
the trafficking pathways of protein nanocapsules, we 
used these Rab proteins as vesicle markers to track the 
intracellular travel pathway of nanoparticles. The 
crosstalk between the endocytosis and exocytosis 
pathway with autophagy has also been extensively 
investigated, through the manipulation of the 
exocytosis and autophagy pathways with inhibitors 
such as 3-MA (autophagy inhibitor) and CQ 
(lysosome inhibitor), which block the degradation of 
the protein nanocapsules. The effects of the protein 
nanocapsules may extensively improve when 
combined with drugs that can block the autophagy 
and exocytosis pathways. 
Materials and methods 
Materials 
Bovine serum albumin, dimethyl sulphoxide 
(DMSO), Chloroquine (CQ), and 3-methyladenine 
(3-MA) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). N-acryloxysuccinimide (NAS), 
acrylamide (AAm), N, N-methylene bisacrylamide 
(BIS), ammonium persulphate (APS), N, N, N’, 
N’-tetramethylethylenediamine (TEMED) and 
Fluorescein isothiocyanate (FITC) were purchased 
from Aladdin Industrial Co. LTD. (Shanghai, China). 
N-(3-Aminopropyl) methacrylamide hydrochloride 
was purchased from Polymer Science, Inc. All other 
chemicals of the highest quality were commercially 
available and used as received. Lyso-Tracker Red was 
purchased from Beyotime Biotechnology (Shanghai, 
China). Antibodies against LC3, Arf-6, Flotillin, 
Cdc42, RhoA, P62, EEA1, Clathrin, Caveolin were 
from Cell Signaling Technology. The antibody against 
LAMP1 was from Santa Cruz Biotechnologies, and the 
antibody against β-actin was obtained from Abmart.  
Plasmid and transfection 
The EGFP-LC3 and DsRed-LC3 plasmids were 
created in our laboratory. The DsRed-Rab5,  
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DsRed-Rab7 and Flag-Rubicon plasmids were 
purchased from Addgene. The KSHV Flag-vBcl-2 
plasmid was kindly provided by Professor Beth 
Levine from the University of Texas Department of 
Medicine. The Rab1-37 genes in the T Vector were 
from Professor Jiahuai Han’s Lab and sub-cloned into 
EGFP-C1 and DsRed-C1, respectively. All plasmids 
were confirmed by automated DNA sequencing. Cells 
were transiently transfected with the plasmids using 
Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. 
Synthesis of nBSA 
The synthesis procedures were similar to 
reference [4]. First, 20 mg of BSA in 4 ml of pH 8, 50 
mM sodium carbonate buffer was reacted with 0.5 mg 
N-acryloxysuccinimide in 50 ml DMSO for 2 h at 
room temperature. Then, the reaction solution was 
thoroughly dialysed against pH 7.0, 20 mM 
phosphate buffer. Using 10 mg acryloylated BSA 
solution at 1 mg/ml, radical polymerization from the 
surface of the acryloylated protein was initiated by 
adding APS dissolved in deoxygenated and deionized 
water and TEMED into the test tube. A specific 
amount of N-(3-Aminopropyl) methacrylamide 
(Apm), AAm and BIS (molar ratio BSA/ Apm/ 
AAm/ BIS/ Aps/ TEMED = 1 / 500 / 2500 / 300 / 
300 / 1200) dissolved in deoxygenated and deionized 
water was added to the test tube over 60 min. The 
reaction was allowed to proceed for another 60 min in 
a nitrogen atmosphere. Finally, dialysis was used to 
remove monomers and initiators. The unmodified 
BSA was removed using ion exchange 
chromatography.  
Characterization of nBSA 
Ion exchange chromatography was performed 
with a DEAE Sephadex A-25. Gel electrophoresis 
results were quantified with ImageQuant LAS4000 
after agarose gel electrophoresis in 0.7% agarose gels. 
TEM images of nanocapsules were obtained with a 
Philips EM120 TEM at 100000X. Before observation, 
nanocapsules were negatively stained using 1% pH 
7.0 phosphotungstic acid (PTA) solution. Zeta 
potential and particle size distribution were measured 
with a Malvern particle sizer Nano-ZS.  
Cell culture 
MCF-7 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented 
with 10% Fetal Bovine Serum (FBS). 
Cellular uptake of nBSA  
FITC was used as a model fluorescent molecule 
and was formulated in nBSA. Non-transfected or 
DsRed-Rab1-38 were incubated with 1 mg/mL 
FITC-label nBSA at 37 ℃ for 20 h. For lysosome 
detection, the cells were incubated with Lyso-Tracker 
Red for 1 h. Then, the cells were washed with PBS 
three times and fixed with 4% paraformaldehyde for 
20 min. Cells were stained with DAPI for 15 min and 
washed three times with PBS. Confocal microscopy 
was performed with a FLUO-VIEW laser scanning 
confocal microscope (Olympus, FV1000, Olympus 
Optical, Japan) in sequential scanning mode using a 
60~100×objective. The operation processes were 
similar to reference [23]. 
Autophagy assays 
Cells were transfected with EGFP-LC3 under the 
indicated conditions and then fixed in 4% 
paraformaldehyde. The percentages of cells with 
fluorescent dots representing EGFP-LC3 translocation 
were counted by confocal microscopy as described 
previously [24-26].  
LC3II protein level was detected using an 
anti-LC3 antibody. 
Immunoblotting 
Immunoblotting analysis was performed as 
previously described [24, 27]. In brief, cell lysates 
were resolved on 12% SDS-PAGE and analyzed by 
immunoblotting using an LC3 antibody, followed by 
enhanced chemiluminescence (ECL) detection 
(Thermo Scientific).  
Immunofluorescence assay  
Briefly, the cells were incubated with the 
following primary antibodies: EEA1, Clathrin, LC3, 
Arf-6, Flotillin, Cdc42, RhoA, P62, EEA1, and 
Caveolin. TRITC and FITC labeled secondary 
antibodies were used to detect the primary antibodies. 
Statistical methodology 
All results are reported as the mean ± S.D of 
three independent experiments. Comparisons were 
performed using two-tailed paired Student’s t tests (* 
P<0.05, ** P<0.01, *** P<0.001).  
Results and discussion 
Preparation and Characterization of BSA 
nanocapsules (nBSA) 
We prepared BSA nanocapsules (nBSA) that 
consist of a single-protein core and thin polymer shell 
anchored covalently to the protein core through in 
situ polymerization [4]. Fig. 1A is a schematic 
illustration of nBSA. The gel electrophoresis results 
indicated that the charge of nBSA was opposite to that 
of native BSA. Native BSA had a negative charge, 
whereas nBSA had positive charge, which 
demonstrates that BSA was completely encapsulated 
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and nBSA was successfully synthesized (Fig. 1B). As 
shown in the TEM image (Fig. 1C), nBSA was 
spherical, with a diameter of approximately 20 nm. 
Dynamic light scattering (DSL) measurements 
indicated that the size of nBSA was uniformly 
distributed and consistent with the TEM results (10.74 
± 0.95 nm) (Fig. 1D). The zeta potential of nBSA was 
measured to be 5.28 ± 0.43 mV (Fig. 1E). The positive 
charge could help nBSA internalize quickly into 
cancer cells. The yield of the protein nanocapsules 
was higher than 95%. 
Endocytosis pathway of protein nanocapsules 
Endocytosis includes clathrin dependent and 
clathrin independent pathways. The clathrin 
independent pathway includes the micropinocytosis, 
caveolin dependent and caveolin independent (Arf-6, 
Flotillin, Cdc42 and RhoA-dependent) pathways [12]. 
To detect the pathways through which the protein 
nanocapsules enter the cells, MCF-7 cells were treated 
with FITC-labeled nBSA for 20 hours. We observed 
many FITC-positive vesicles containing nBSA within 
the cells. We then detected the localization of the 
FITC-positive vesicles with Clathrin, Caveolin, Arf-6, 
Flotillin, Cdc42 and RhoA- positive vesicles. We 
found that FITC-positive vesicles co-localized with 
Arf-6 positive vesicles, but not with clathrin, caveolin, 
Flotillin, Cdc42 or RhoA- positive vesicles (Fig. 2A 
and Fig. S1A-E). These data indicated that the cells 
uptake protein nanocapsules through Arf-6 
dependent endocytosis but not through clathrin- or 
caveolin-dependent pathway endocytosis.  
The classic endocytosis pathways include EEs, 
LEs and lysosomes. Rab5 and its effector EEA1 have 
been widely used as a marker of EEs, whereas Rab7 is 
a marker of LEs [17]. Therefore, we used EEA1 and 
DsRed-Rab5 to label the EEs and DsRed-Rab7 and 
Rab9 to label LEs. We then treated MCF-7 cells 
transfected with the vector and DsRed-Rab7 with 
FITC-labeled nBSA for 20 h. We found that the 
FITC-labeled nBSA containing vesicles co-localized 
with EEA1 and DsRed-Rab5-labeled EEs (Fig. 2B, C). 
FITC-labeled nBSA containing vesicles also 
co-localized with DsRed-Rab7 and Rab9 positive LEs 
(Fig. 2D, E). Lyso-Tracker Red probes were used to 
detect lysosomes. As expected, FITC-positive vesicles 
co-localized with the lysosomes (Fig. 2F). These data 
demonstrated that the protein nanocapsules were 
taken up by the cells through Arf-6 dependent 
endocytosis, transported to LEs and EEs, and finally 
degraded through the classic endocytosis pathway.  
 
 
Figure 1. Formation of nBSA. (A) Schematic illustration of nBSA. (B) Gel electrophoresis results of BSA and nBSA. (C) TEM image of nBSA. (D) Size distribution of nBSA 
determined with DLS. (E) Zeta potential distribution of nBSA. Scale bars: 50 nm. 
 
 Theranostics 2016, Vol. 6, Issue 12 
 
http://www.thno.org 
2103 
 
Figure 2. The nBSA enters the cells through Arf-6 dependent endocytosis. (A, B) Confocal images of MCF-7 cells, which were treated with 1 mg/mL FITC-labeled 
BSA-nanocapsules for 20 hours. Arf-6 and EEA1 were detected with primary antibodies against Arf-6 and EEA1, respectively. (C, D, E) DsRed-Rab5, DsRed-Rab7, DsRed-Rab9 
transfected MCF-7 cells were treated with 1 mg/mL FITC-labeled BSA-nanocapsules for 20 h. (F) For lysosome detection, the MCF-7 cells were treated with 1 mg/mL 
FITC-labeled BSA-nanocapsules for 20 h and then co-treated with Lyso-Tracker Red probes for 30 min. Scale bars: 10 μm. 
 
In addition to Rab5 and Rab7, more than 30 
types of Rab proteins have been identified. These Rab 
proteins have specific functions in vesicle trafficking 
[22]. Among these Rab proteins, Rab 18, 21, 23 and 34 
have also been reported to be involved in the 
endocytosis pathway [22, 28]. However, only Rab5 
and Rab7 have been widely detected in endocytosis 
for tracking the travel pathway of the nanoparticles. 
To investigate the other intra-trafficking pathways of 
protein nanocapsules, we treated the DsRed Rab18, 
21, 23 and 34 transfected MCF-7 cells with 
FITC-labeled nBSA (Table 1). We found that 
FITC-positive vesicles co-localized with 
DsRed-Rab18, 23, and 34 positive vesicles but not 
Rab21 (Fig. 3 and S2). Micropinocytosis is a type of 
clathrin independent endocytosis, which is controlled 
by Rab34. Thus, Rab34 is a marker of 
micropinocytosis [21, 22]. We observed that Rab34 
positive vesicles colocalized well with FITC-labeled 
nBSA (Fig. 3A). To investigate the downstream 
pathway of micropinocytosis, we detected the 
co-localization between DsRed-Rab34 with the 
markers of the classic endocytosis pathway (EEA1, 
EGFP-Rab7 and lysosome). Notably, we found that 
Rab34 could co-localize with EGFP-Rab7 and 
lysosomes but not with EEA1 (Fig. 3B and Fig.S2A, B). 
These data indicated that micropinocytosis (Rab34 
positive)-LEs (Rab7 positive)-lysosomes might be a 
novel endocytosis pathway involved in the turnover 
of protein nanocapsules. 
Rab18 is a well-known marker for lipid droplets 
in adipocytes [29]. Rab18 is associated with lipid 
droplets and the release of lipids from lipid droplets 
in adipocytes and is therefore an excellent marker to 
follow the dynamics of lipid droplets [21]. Notably, 
we observed that Rab18 positive vesicles merged with 
FITC-nBSA positive vesicles (Fig. 3C). To investigate 
the relationship between Rab18-positive vesicles and 
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the classic endocytosis pathway, we examined the 
co-localization of DsRed-Rab18 and the markers of the 
classic endocytosis pathway (EEA1, EGFP-Rab7 and 
lysosomes). We found that Rab18 could co-localize 
with EEA1 and lysosomes but not with EGFP-Rab7 
(Fig. 3D-F). To confirm this result, we examined the 
co-localization of DsRed-Rab18 with another LE 
marker, the Rab protein EGFP-Rab9. DsRed-Rab18 
also did not co-localize with EGFP-Rab9 (Fig.S3A). 
Therefore, the LEs-liposome (Rab18 
positive)-lysosome pathway is another novel 
endocytosis pathway involved in the turnover of the 
protein nanocapsules. 
 
Table 1. Endocytosis marker co-localization with FITC-labeled nBSA. 
Protein Markers Co-localization with 
nBSA 
Subcellular localization  Function 
Membrane Internalization    
Clathrin NO Cell membrane  Clathrin-dependent endocytosis 
Caveolin NO Cell membrane Caveolin-dependent endocytosis 
RhoA NO Cell membrane RhoA-dependent endocytosis 
Cdc42 NO Cell membrane Cdc42-dependent endocytosis 
Flotillin NO Cell membrane Flotillin-dependent endocytosis 
Arf6 YES Cell membrane Arf6-dependent endocytosis 
Rab proteins in trafficking    
Rab1 NO ER–Golgi intermediate ER–Golgi trafficking 
Rab2 NO ER–Golgi intermediate ER–Golgi trafficking 
Rab3 NO TGN-apico-lateral membranes Exocytosis of secretory granules and vesicles from TGN to 
apico-lateral 
Rab4 NO Early and recycling endosomes Endocytic recycling to plasma membrane 
Rab5 YES Early endosome Endocytic internalization and early endosome fusion 
Rab6 NO Intra-Golgi Intra-Golgi transport 
Rab7 YES Late endosome Control late endocytic trafficking 
Rab8 YES Median Golgi and TGN Basolateral protein transport from median Golgi and TGN 
Rab9 YES Late endosome Transport from late endosomes to trans-Golgi 
Rab10 YES Median Golgi and TGN Basolateral protein transport from median Golgi and TGN 
Rab11 YES Recycling endosomes Transport from the Golgi, and apical and basolateral 
endocytic recycling 
Rab12 Not Tested Peripheral region of cell to perinuclear 
centrosomes 
Transport from peripheral region of cell to perinuclear 
centrosomes 
Rab14 NO Early endosomes and Golgi Transport between early endosomes and Golgi 
Rab15 Not Tested Early and recycling endosomes Inhibitor of endocytic internalization 
Rab17 Not Tested Epithelial-specific; apical recycling 
endosome 
Transport through apical recycling endosomes 
Rab18 YES ER and liposome Liposome formation 
Rab20 YES Recycling endosome In apical endocytosis/recycling 
Rab21 NO Cell membrane Focal adhesion site transport 
Rab22 YES Early endosomes and TGN Transport between TGN and early endosomes and vice versa 
Rab23 YES Plasma membranes and early endocytic 
vesicles 
Transport between plasma membranes and early endocytic 
vesicles 
Rab24 YES ER/cis-Golgi region and on late 
endosomal structures 
Autophagy-related processes 
Rab25 YES Apical recycling endosome Transport through apical recycling endosomes 
Rab26 NO TGN-apico-lateral membranes Exocytosis of secretory granules and vesicles from TGN to 
apico-lateral membranes 
Rab31 YES Early endosomes and TGN Transport between TGN and early endosomes and vice versa 
Rab32 NO Melanosomes Biogenesis of melanosomes 
Rab38 NO Melanosomes Biogenesis of melanosomes 
Rab34 YES Micropinocytosis Biogenesis of micropinocytosis 
Rab35 YES Recycling endosomes  Apical endocytic recycling 
Rab43 NO ER–Golgi intermediate ER–Golgi trafficking 
Autophagy    
LC3 YES Autophagosome Autophagosome formation 
 
 
 
 Theranostics 2016, Vol. 6, Issue 12 
 
http://www.thno.org 
2105 
 
Figure 3. The nBSA enters the cells through the micropinocytosis-LEs-lysosome pathway. (A, B) DsRed-Rab34 transfected MCF-7 cells were then treated with 1 mg/mL 
FITC-labeled BSA-nanocapsules for 20 h; DsRed-Rab34 cells were co-transfected with EGFP-Rab7. (C-F) DsRed-Rab18 transfected MCF-7 cells were then treated with 1 mg/mL 
FITC-labeled BSA-nanocapsules for 20 h; EEA1 was then detected with a primary antibody against EEA1; DsRed-Rab18 cells were co-transfected with EGFP-Rab7; for lysosome 
detection, the MCF-7 cells were transfected with DsRed-Rab18 and then co-treated with Lyso-Tracker Red probes for 1 h. Scale bars: 10 μm. 
 
Rab23 is an inhibitor of hedgehog signaling; 
however, the function of Rab23 in endocytosis is 
poorly understood [30-32]. Rab23 is supposed to be 
involved in the transport system between plasma 
membranes and early endocytic vesicles [21]. We 
observed that Rab23 positive vesicles merged well 
with FITC-labeled protein nanocapsules (Fig. S4A). 
Therefore, we examined the co-localization of DsRed 
Rab23 and cell membrane markers (clathrin, caveolin, 
Arf-6, Flotillin, Cdc42 and RhoA) and EEs (EEA1). 
Rab23 colocalized with clathrin, Arf-6, Flotillin, 
Cdc42, RhoA and EEA1, but not caveolin (Fig.S4B-G). 
These data indicated that Rab23 might have an 
important function in the trafficking between the cell 
membrane and EEs. Rab23 may help Arf-6 positive 
vesicles transport protein nanocapsules to EEs. 
Recycling endosome pathway transport 
protein nanocapsules 
Recycling endosomes are responsible for the 
redelivery of protein receptors from EEs back to the 
cell membrane [28]. Rab proteins, including Rab4, 11, 
15, 17, 20, 25 and 35, have been reported to regulate 
the formation of recycling endosomes [21, 28]. Among 
these Rab proteins, Rab11 and Rab35 mediate slow 
endocytic recycling directly from EEs [22, 28]. Rab4 
mediates fast endocytic recycling from EEs [22, 28]. 
Rab15, 17, 20 and Rab25 control trafficking through 
the apical recycling endosomes to the apical plasma 
membrane [22, 28, 29]. It is not known whether 
nanoparticles can be released from the cells through 
the recycling endosome system. To determine 
whether protein nanocapsules could be delivered by 
recycling endosomes, we treated the DsRed-Rab4, 11, 
20, 25 and 35 transfected MCF-7 cells with 
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FITC-labeled nBSA for 20 h. We examined the 
co-localization between nBSA and these Rab proteins 
(Table 1). We found that FITC-positive nBSA localized 
with Rab11 and 35 positive slow recycling endosomes 
and Rab20 and 25 positive apical recycling endosomes 
(Fig. 4A, B and S5A). However, FITC-positive protein 
nanocapsules did not co-localize with Rab4 positive 
fast recycling endosomes (Fig. S5B). These data 
indicated that nBSA could be transported out of the 
cells through the slow (Rab11 and Rab35 positive) and 
apical (Rab20 and Rab25 positive) recycling endosome 
pathways to release the nanoparticles out of the cells.  
According to our data, we determined that 
protein nanoparticles could enter the cells through 
Arf-6 dependent endocytosis and Rab34 positive 
micropinocytosis (Fig. 4E). Two pathways are 
involved in protein nanocapsule turnover: the 
EEs-LEs-lysosome and the EEs-Liposome-lysosome 
pathway (Fig. 4E). Protein nanocapsules could be 
transported out of the cells through the slow and 
apical recycling endosome pathways to release the 
nanoparticles out of the cells (Fig. 4E). 
 
 
Figure 4. nBSA through the recycling pathway. (A, B) DsRed-Rab11 transfected MCF-7 cells were then treated with 1 mg/mL FITC-labeled BSA-nanocapsules for 20 h; 
DsRed-Rab35 transfected MCF-7 cells were then treated with 1 mg/mL FITC-labeled BSA-nanocapsules for 20 h. (C, D) DsRed-Rab20 transfected MCF-7 cells were then treated 
with 1 mg/mL FITC-labeled BSA-nanocapsules for 20 h; DsRed-Rab25 transfected MCF-7 cells were then treated with 1 mg/mL FITC-labeled BSA-nanocapsules for 20 h. Scale 
bars: 10 μm. (E) Schematic representation of the pathway through which the BSA-nanocapsules enter the cells, turnover in the cells and transport out of the cells. 
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Exocytosis pathway of protein nanocapsules 
Exocytosis is an energy-consuming process by 
which cells direct the contents of secretory vesicles out 
of the cell membrane and into the extracellular space 
[19, 33]. Some Rab proteins regulate the formation, 
transport and fusion of these secretory vesicles and 
have become markers for some secretory vesicles [21, 
22]. Rab3, Rab26, Rab27 and Rab37 mediate classic 
secretory vesicles [21, 22]. Rab8, Rab10 and Rab14 
participate in GLUT4 vesicle translocation [21, 22]. 
Rab27, Rab32 and Rab38 mediate the translocation of 
melanosomes to the cell periphery [22, 28]. To 
investigate whether protein nanocapsules could be 
transported out of the cell through the exocytosis 
pathway, we treated DsRed-Rab3, Rab26, Rab37, 
Rab8, Rab10, Rab14, Rab27, Rab32, and Rab38 
transfected MCF-7 cells with FITC-labeled nBSA for 
20 h (Table 1). We found that FITC-positive nBSA 
co-localized with DsRed Rab8 and Rab10-positived 
vesicles (GLUT4 vesicle) (Fig. 5A and S7A).  
 
 
Figure 5. nBSA through the exocytosis pathway. (A) DsRed-Rab8 transfected MCF-7 cells were treated with 1 mg/mL FITC-labeled nBSA for 20 h; DsRed-Rab10 transfected 
MCF-7 cells were then treated with 1 mg/mL FITC-labeled BSA-nanocapsules for 20 h. (B) DsRed-Rab22 transfected MCF-7 cells were treated with 1 mg/mL FITC-labeled nBSA 
for 20 h; DsRed-Rab31 transfected MCF-7 cells were then treated with 1 mg/mL FITC-labeled BSA-nanocapsules for 20 h. (C) Schematic representation of how the cells use the 
Rab8, Rab10-positived GLUT4 transport vesicles pathway to transport protein nanocapsules out of the cells. 
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However, FITC-positive protein nanocapsules 
neither co-localized with DsRed Rab3 and Rab26 
positive secretory vesicles (Fig.S6A-C) nor Rab32 and 
Rab38 positive melanosomes (Fig.S6D-F). These data 
indicated that protein nanocapsules could be secreted 
to the extracellular environment through the Rab8 
and Rab10-positive GLUT4 vesicle pathway.  
DsRed Rab8 and Rab10-positived GLUT4 
transport vesicles are formed from the TGN [22]. 
Thus, the protein nanocapsules should be transported 
into the Golgi, and then sequestered in GLUT4 
transport vesicles. The Golgi body could receive the 
components from EEs and LEs [22]. Rab14, Rab22 and 
Rab31 positive vesicles are transport vesicles from EEs 
to the TGN [22]. Rab9 positive vesicles are responsible 
for the transportation from LEs to the TGN [20]. To 
test whether the protein nanocapsules were 
transported from EEs to TGN, we treated the 
DsRed-Rab14, DsRed-Rab22 and DsRed-Rab31 
transfected MCF-7 cells with FITC-labeled nBSA for 
20 h. We observed that DsRed-Rab22 and 
DsRed-Rab31 positive vesicles co-localized with nBSA 
but not Rab14 (Fig. 5B and S7B). To test whether the 
protein nanocapsules were transported from LEs to 
the TGN, we treated the DsRed-Rab9 and 24 
transfected MCF-7 cells with FITC-labeled nBSA for 
20 h. We found that DsRed-Rab9, DsRed-Rab22 and 
DsRed-Rab31 positive vesicles could co-localize with 
nBSA (Fig. 2E and S7C). These data indicated that the 
TGN might receive the protein nanocapsules from 
both of EEs and LEs.  
Next, we also tested Rab1 and Rab44 positive 
vesicles, which are responsible for ER-TGN 
trafficking. However, we observed that DsRed-Rab1 
and Rab44 positive vesicles did not transport the 
protein nanocapsules (Fig. S8A, B). Rab6 mediates 
transport in the Golgi body; however, Rab6 positive 
vesicles did not transport nBSA (Fig. S8C). These data 
indicated that the Golgi body might receive protein 
nanocapsules from both EEs and LEs. Then, the cells 
use the Rab8 and Rab10-positive GLUT4 transport 
vesicles pathway to transport protein nanocapsules 
out of the cells (Fig. 5C). 
Autophagy pathway of protein nanocapsules 
Autophagy is a cellular process for degrading 
protein aggregates, damaged organelles such as 
damaged mitochondria, and invading pathogens such 
as viruses [18, 34]. Previously, we reported that 
autophagy also could sequester some biodegradable 
nanoparticles, such as PLGA-based nanoparticles and 
micelles [25, 35, 36]. Because the components and 
structure of protein nanocapsules are similar to 
protein aggregates, autophagy may also sequester 
these protein nanocapsules [37]. To measure 
autophagy, we examined autophagosome 
(LC3-positive vesicle) formation and LC3II protein 
levels [38]. When autophagy is initiated, LC3 is cut on 
its C-terminal end to produce the LC3II protein, 
which is then transferred to the autophagosome [38]. 
To investigate the relationship between protein 
nanocapsules and autophagy, we transfected cells 
with EGFP-LC3. To detect whether the protein 
nanocapsules induced autophagy, EGFP-LC3 
transfected MCF-7 cells were incubated with nBSA for 
20 h. Afterwards, substantial autophagosomes were 
induced within the cells (Fig. 6A). LC3-II protein 
levels were also increased in the cells (Fig. 6A). To 
further investigate whether protein nanocapsules 
could be degraded through the autophagy pathway, 
we used red fluorescent-labeled LC3 protein 
(DsRed-LC3) to detect autophagy and FITC-labeled 
nBSA. DsRed-LC3 transfected MCF-7 cells were 
treated with FITC-labeled nBSA for 20 h. After 20 h 
incubation, the FITC-labeled nBSA were sequestered 
within DsRed-LC3 positive autophagosomes (Fig. 6B). 
P62, also known as sequestosome 1(SQSTM1), is one 
of the most characterized substrates of selective 
autophagy [38]. LC3 directly interacts with 
P62/SQSTM1 and captures P62 on the isolation 
membrane [38]. P62 is an adapter molecule that 
selectively recognizes and binds the substrates of 
autophagy, such as proteins, organelles and microbes 
[20-22]. Because protein nanocapsules are similar to 
protein aggregates, we hypothesized that 
P62/SQSTM1 might mediate the selective autophagy 
of the protein nanocapsules. As expected, we found 
that the FITC-positive vesicles merged with 
P62/SQSTM1 in the cells (Fig. 6C). However, 
P62/SQSTM1-protein merged with autophagosomes 
perfectly (Fig. 6D). Finally, the autophagosomes were 
then translocated to fuse with the lysosome for 
degradation (Fig. 6E). These data indicated that 
P62/SQSTM1 selectively captures the nanocapsules 
and delivers them to autophagosomes. These data 
demonstrated that the nBSA could be degraded 
through the autophagy pathway. 
Crosstalk between endocytosis, exocytosis and 
autophagy 
In recent years, studies have shown that some 
Rab proteins are involved in the regulation of 
autophagy, such as Rab5, Rab7, Rab8, Rab9, Rab11, 
Rab20, Rab32 and Rab33 [39]. These findings suggest 
that the endocytosis and exocytosis pathways may 
have crosstalk with autophagy. In selective 
autophagy, P62 selects the target and LC3 selects P62 
[38]. We have observed that autophagosomes contain 
biodegradable nanoparticles, such as PLGA-based 
NPs, micelles, and protein nanocapsules [35, 36]. The 
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autophagosome may sequester the nanoparticles 
directly. However, there may be another mechanism 
in which autophagosomes fuse with Rab protein 
positive vesicles of endocytosis and exocytosis. To 
investigate whether autophagosomes have crosstalk 
with these Rab positive vesicles, we co-transfected 
MCF-7 cells with EGFP-LC3 and DsRed Rab proteins 
representing various vesicles of endocytosis and 
exocytosis. The nBSA were internalized into the cells 
through Arf-6 dependent endocytosis and Rab34 
positive micropinocytosis. Then, the protein 
nanocapsules could be delivered to lysosomes by 
three different pathways: (I) EEs (EEA1 and Rab5 
positive)-LEs (Rab7 positive)-lysosome, the classic 
endocytosis pathway; (II) the Micropinocytosis 
(Rab34 positive)-LEs (Rab7 positive)-lysosome 
pathway; (III) the EE-liposome (Rab18)-lysosome 
pathway. We observed that EGFP-LC3 positive 
autophagosomes could merge with Rab23, Rab34, 
Rab7 and Rab18 positive vesicles (Fig. 7A-D). These 
data indicated that autophagosomes might receive 
protein nanocapsules through these endocytosis- 
related vesicles. 
We also tested whether the recycling endosomes 
had crosstalk with autophagosomes. We previously 
mentioned that protein nanocapsules could be 
sequestered in slow recycling endosomes and apical 
recycling endosomes. To determine whether 
autophagy had crosstalk with recycling endosomes, 
we co-transfected the MCF-7 cells with EGFP-LC3 and 
DsRed-Rab4 (fast recycling endosome), Rab11, Rab35 
(slow recycling endosome), Rab15, Rab17 and Rab25 
(apical recycling endosome). We found that only 
DsRed-Rab11 and Rab35 co-localized with EGFP-LC3 
positive autophagosomes (Fig. 7E, F). These data 
indicated that autophagosomes might also receive the 
protein nanocapsules through recycling endosomes. 
 
 
Figure 6. nBSA induces autophagy and are sequestered by the autophagosomes. (A) Representative images and quantification of MCF-7 cells with EGFP-LC3 vesicles 
(autophagosomes). EGFP-LC3 transfected cells were treated with 1 mg/mL non-labeled nBSA for 20 h. Scale bars: 10 μm. Data are provided as the means ± SD. *P < 0.05, **P 
< 0.01, ***P < 0.0001 compared to controls. (B) LC3I/II protein levels were analyzed by western blotting in the MCF-7 cells treated in (A). (C) DsRed-LC3 transfected MCF-7 
cells were then treated with 1 mg/mL FITC-labeled nBSA for 20 h; MCF-7 cells were treated with 1 mg/mL FITC-labeled nBSA for 20 h and then P62 was detected with a primary 
antibody against P62. (D) DsRed-LC3 transfected MCF-7 cells and then P62 was detected with a primary antibody against P62. (E) EGFP-LC3 transfected MCF-7 cells were 
co-treated with Lyso-Tracker Red probes for 1 h. The autophagosomes fuse with lysosomes (arrows). The above images are enlarged from the white outline in the images below. 
Scale bars: 10 μm. 
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Figure 7. Crosstalk between endocytosis, exocytosis and autophagy. (A-H) EGFP-LC3 cells were co-transfected with DsRed-Rab23, DsRed-Rab34, DsRed-Rab7, DsRed-Rab18, 
DsRed-Rab11, DsRed-Rab35, DsRed-Rab8 and DsRed-Rab10, respectively. Scale bars: 10 μm. 
 
We also demonstrated that protein nanocapsules 
could be sequestered in GLUT4 transport vesicles. To 
detect whether autophagy had crosstalk with 
exocytosis, we co-transfected the MCF-7 cells with 
EGFP-LC3 and DsRed-Rab3, Rab26, Rab37 (Secretory 
vesicles), Rab8, Rab10, Rab14 (GLUT4 vesicles), 
Rab32, and Rab38 (melanosomes). We observed that 
Rab8 and Rab10 positive GLUT4 vesicles co-localized 
with autophagosomes (Fig. 7J, H). DsRed-Rab3 and 
Rab26 positive secretory vesicles and Rab32 and 
Rab38 positive melanosomes did not merge with 
EGFP-LC3 positive autophagosomes (Fig.S9A-C). 
These data suggest that autophagosomes may receive 
the protein nanoparticles from Rab11 positive slow 
recycling endosomes or Rab8 positive GLUT4 
vesicles.  
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Inhibiting autophagy blocks the degradation of 
nBSA by the auto-lysosome pathway 
Protein nanocapsules must enter the cytoplasm 
to execute their function, particularly the protein 
molecules. However, the cellular trafficking of the 
protein nanocapsules will transport them to 
lysosomes for degradation from endocytosis and 
autophagy. 
Therefore, inhibition of the degradation of 
protein nanocapsules by lysosomes will be important. 
The class III PI3K complex, including Atg14L, Beclin1, 
hVps34, hVps15, UVRAG, Rubicon and Bcl-2 family 
members, is a major complex that regulates the 
autophagy and endosome pathways [40]. Kaposi’s 
sarcoma-associated herpes virus Bcl-2 (KSHV vBcl-2) 
can significantly inhibit autophagy [24]. Therefore, we 
first investigated whether vBcl-2 could inhibit 
autophagy and block the transport of protein 
nanocapsules by autophagy. As expected, 
overexpression of Flag-vBcl-2 inhibited the formation 
of autophagosomes; FITC-labeled nBSA could not be 
sequestered by the autophagosomes (Fig. 8A, B). 
3-MA is a chemical inhibitor of hVps34 that can 
inhibit the activity of the Class III PI3K complex and 
the initiation of autophagy [18]. Treatment of the cells 
with 3-MA also inhibited the formation of 
autophagosomes and blocked the degradation of 
protein nanocapsules by the autophagy pathway (Fig. 
8 C, D).  
 
 
 
Figure 8. Inhibiting autophagy and exocytosis enhances the effect of protein nBSA. (A, B) DsRed-LC3 transfected MCF-7 cells were treated with 1 mg/mL FITC-labeled nBSA 
for 20 h; DsRed-LC3 cells were co-transfected with Flag-vBcl-2 and then treated with 1 mg/mL FITC-labeled nBSA for 20 h. (C, D) Representative images of MCF-7 cells with 
DsRed-LC3 vesicles. The DsRed-LC3 transfected MCF-7 cells were co-treated 10 μM 3-MA and 30 μM CQ, respectively. (E, F) DsRed-Rab7 transfected MCF-7 cells were then 
treated with 1 mg/mL FITC-labeled nBSA for 20 h; The DsRed-Rab7 transfected MCF-7 cells were co-treated with 30 μM CQ. Scale bars: 10 μm. 
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Figure 9. Schematic representation of the degradation pathway of protein nanocapsules in cell. Rab34 positive micropinocytosis, Rab7 and Rab9 positive late endosome, Rab18 
positive liposome, Rab11 and Rab35 positive slow recycling endosome, Rab8 and Rab10 positive GLUT4 vesicles co-localize with autophagosomes. 
 
Chloroquine is a lysosome tropic agent that 
prevents endosomal acidification and disrupts 
lysosomes [36]. Therefore, because CQ blocked the 
fusion of autophagosomes with lysosomes, numerous 
autophagosomes accumulated in the cytoplasm. 
Treatment of the cells with CQ also blocked the 
degradation of protein nanocapsules by lysosomes 
(Fig. 8D). Because Rab7 positive LEs also must fuse 
with lysosomes for the final degradation of 
nanocapsules, disruption of lysosomes also resulted 
in the accumulation of LEs. Treatment of the cells with 
CQ for 20 h caused the DsRed-Rab7 positive LEs to 
accumulate, and prevented the degradation of the 
protein nanocapsules by lysosomes (Fig. 8E, F). Thus 
inhibition of the autophagy and endocytosis 
pathways by inhibitors could block the degradation of 
protein nanocapsules by lysosomes (Fig. 9). 
Conclusions 
In this paper, we determined that FITC-labeled 
nBSA are internalized by cells mainly through 
Arf6-dependent endocytosis and Rab34 mediated 
micropinocytosis. Moreover, we used more than 30 
Rab proteins to investigate the detail intracellular 
trafficking pathway of nBSA. In addition to the classic 
pathway, we identified two other novel transport 
pathways: micropinocytosis pathway and liposome 
pathway. Cell also used slow endocytic recycling and 
GLUT4 exocytosis vesicles transport the nBSA out of 
the cells. Autophagy also sequester the nBSA through 
p62 and other endosome vesicles. Using an autophagy 
inhibitor (3-MA) and lysosome inhibitor (CQ) to block 
these transport pathways eliminated the degradation 
of nanoparticles through lysosomes. Rab family 
proteins are specific markers on the endo trafficking 
vesicles, which are excellent vesicle markers to 
investigation the detail intracellular trafficking of the 
nanoparticles. These new trafficking findings will 
provide new targets to interfere the cellular behaver 
of the nanoparticles, and improve the therapeutic 
effect of nanomedicine. 
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